Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe) (NIMBLe)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03461952
Recruitment Status : Active, not recruiting
First Posted : March 12, 2018
Last Update Posted : January 26, 2022
Cancer Research Institute, New York City
Bristol-Myers Squibb
Personal Genome Diagnostics
Information provided by (Responsible Party):
Canadian Cancer Trials Group

Brief Summary:
The purpose of this study is to determine the safety and effectiveness of nivolumab alone or in combination with ipilimumab in patients with metastatic or unresectable tumors harbouring mutations in genes, POLE and POLD1. These mutations will be determined by plasma cfDNA. Nivolumab and ipilimumab have been given to patients across multiple types of cancer, and safe doses and schedules have been determined.

Condition or disease Intervention/treatment Phase
Advanced Solid Tumors Drug: Nivolumab Drug: Ipilimumab Phase 2

Detailed Description:
Participants in this study have been diagnosed with metastatic or unresectable solid tumors that have a mutation in POLE and/or POLD1. Nivolumab alone or in conjunction with ipilimumab is predicted to be effective against tumors with POLE and/or POLD1 mutations as these genetic changes cause increased rates of mutations in the DNA of tumor cells. These high mutation rates have been associated with response to immunotherapy agents such as nivolumab and ipilimumab.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 4 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Open Label, Randomized Non-Comparative Trial of Nivolumab Alone or in Combination With Ipilimumab for the Treatment of Patients With Advanced Hypermutated Solid Tumors Detected by a Blood Based Assay
Actual Study Start Date : August 28, 2018
Actual Primary Completion Date : June 1, 2021
Estimated Study Completion Date : June 30, 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Nivolumab
240mg Q2W
Drug: Nivolumab

Experimental: Nivolumab + Ipilimumab
Nivolumab 240mg Q2Wk + Ipilimumab 1mg/kg Q6W
Drug: Nivolumab

Drug: Ipilimumab

Primary Outcome Measures :
  1. Objective Response Rate by RECIST 1.1 [ Time Frame: 36 months ]

Secondary Outcome Measures :
  1. Efficacy as measured by objective response rate [ Time Frame: 36 months ]
    Will be reported using percentages over all randomized patients with 90% exact confidence intervals

  2. Duration of response [ Time Frame: 36 months ]
    Response rates will be reported using percentages over all patients who have received at least one dose of treatment with 90% exact CI of each arm in a non-comparative analysis

  3. Number and severity of adverse events using CTCAE 5.0 [ Time Frame: 36 months ]
    AE rates will be reported using percentages with 90% exact CI

  4. Correlation between POLE or POLD1 mutations in tumor and POLE or POLD1 mutations in blood [ Time Frame: 36 months ]
    Will be assessed by Fischer's exact test in each arm

  5. To evaluate response by iRECIST [ Time Frame: 36 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have histologically confirmed advanced (metastatic or unresectable) solid tumors.
  • Patients must have received at least 1 standard cancer therapy for their tumor type and progressed on their most recent regimen; patients may be treatment naïve if they refuse standard treatment or there is no standard treatment for their cancer.
  • Prior adjuvant/neoadjuvant therapy with curative intent is considered a prior therapy if disease recurrence occurs within at least 6 months.
  • Patients may not have received prior immunotherapy
  • Patients must consent to blood collection for testing after registration by a central reference laboratory.
  • Patients must have clinically and/or radiologically documented disease with at least one lesion measurable as defined by RECIST 1.1.
  • Patients must be ≥ 18 years of age.
  • ECOG performance status 0 or 1.
  • Patients must have adequate hematology and organ function
  • Patient consent for screening must be appropriately obtained in accordance with applicable local and regulatory requirements.
  • Patients must have solid tumors that demonstrate POLE or POLD1 mutations identified at study entry via plasma cfDNA testing or tumor tissue testing for POLE and POLD1 mutations. A CLIA-certified testing of tumor tissue demonstrating POLE or POLD1 mutation can qualify for eligibility and randomization, however, plasma will be submitted for central cfDNA testing. In the event of discordance between tissue and central laboratory testing, the patient will continue in study but will not be included in the primary analysis. These patients will however be included in the secondary analysis.
  • Patients must have recovered to ≤ grade 1 from all reversible toxicity related prior systemic or radiation therapy and have a 2 weeks washout.
  • Previous major surgery is permitted provided that it has been at least 28 days prior to patient registration and that wound healing has occurred.
  • White Blood Cells ≥ 2.0 x 109/L (2000/µL)
  • Absolute neutrophils ≥ 1.5 x 109/L (1500/µL)
  • Platelets ≥ 100 x 10^9/L (100 x103/µL)
  • Hemoglobin ≥80 g/L* (8.0 g/dL)
  • Bilirubin ≤ 1.5 x ULN (upper limit of normal)**
  • AST and/or ALT ≤ 3 x ULN
  • Serum creatinine ≤ 1.5 x ULN or: Creatinine clearance ≥40 mL/min
  • Patients must be willing to consent to provision of archival tissue
  • Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements
  • Patients must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the trial.
  • In accordance with CCTG policy, protocol treatment is to begin within 2 working days of patient randomization.
  • Women of childbearing potential (WOCBP) and men who are sexually active with WOCBP must have agreed to use a highly effective contraceptive method

Exclusion Criteria:

  • Patients with a history of other untreated malignancies or malignancies, which required therapy within the past 2 years. Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen may be eligible after consultation with the CCTG.
  • Patients with primary CNS tumors are not eligible.
  • Patients with active brain metastases or leptomeningeal metastases are not eligible. Patients with brain metastases are eligible if these have been treated and clinically stable. There must also be no requirement for immunosuppressive doses of systemic corticosteroids (> 10 mg/day prednisone equivalents). Physiologic replacement doses of systemic corticoidsteroids are permitted, even if >10mg/day prednisone equivalents
  • History of primary immunodeficiency, history of allogenic organ transplant that requires therapeutic immunosuppression and the use of immunosuppressive agents within 14 days of study drug administration*
  • Active or prior documented autoimmune or inflammatory disorders. Including, inflammatory bowel disease (e.g. colitis or Crohn's disease), diverticulitis with the exception of diverticulosis, celiac disease or other serious gastrointestinal chronic conditions associated with diarrhea), systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome (granulomatosis with polyangiitis), rheumatoid arthritis, hypophysitis, uveitis, etc., within the past 3 years prior to the start of treatment. Patients with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions considered to be of low risk for recurrence are permitted to enroll.
  • History of hypersensitivity to nivolumab or ipilimumab or any excipient.
  • Any previous treatment with a PD-1 or anti-PD-L1, anti-PD-L2 inhibitor, including nivolumab or an anti-CTLA4, including ipilimumab, or drug specifically targeting T-cell stimulation or immune checkpoint pathways.
  • Patients with serious illnesses or medical conditions which would not permit the patient to be managed according to the protocol (including corticosteroid administration), or would put the patient at risk. This includes but is not limited to:

    • History of significant neurologic or psychiatric disorder which would impair the ability to obtain consent or limit compliance with study requirements.
    • Active infection requiring systemic therapy; (including any patient known to have active hepatitis B, hepatitis C or human immunodeficiency virus (HIV) or tuberculosis or any infection requiring systemic therapy).
    • Active peptic ulcer disease or gastritis
    • Active pneumonitis.
  • Patients receiving concurrent treatment with other anti-cancer therapy or other investigational anti-cancer agents.
  • Patients who have experienced untreated and/or uncontrolled cardiovascular conditions and/or have symptomatic cardiac dysfunction (unstable angina, congestive heart failure, myocardial infarction within the previous year or cardiac ventricular arrhythmias requiring medication, history of 2nd or 3rd degree atrioventricular conduction defects).
  • Pregnant or lactating women.
  • Men who are sexually active with women of childbearing potential and women of childbearing potential must agree to use adequate contraception.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03461952

Layout table for location information
United States, New York
Columbia University Medical Center
New York, New York, United States, 10032
Canada, Alberta
Tom Baker Cancer Centre
Calgary, Alberta, Canada, T2N 4N2
Canada, British Columbia
BCCA - Vancouver Cancer Centre
Vancouver, British Columbia, Canada, V5Z 4E6
Canada, Ontario
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, Canada, L8V 5C2
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada, K1H 8L6
University Health Network
Toronto, Ontario, Canada, M5G 2M9
Sponsors and Collaborators
Canadian Cancer Trials Group
Cancer Research Institute, New York City
Bristol-Myers Squibb
Personal Genome Diagnostics
Layout table for investigator information
Study Chair: Naiyer Rizvi Thoracic Oncology and Immunotherapeutics, Columbia University Hospital
Layout table for additonal information
Responsible Party: Canadian Cancer Trials Group Identifier: NCT03461952    
Other Study ID Numbers: I235
0001 ( Other Identifier: Cancer Research Institute )
First Posted: March 12, 2018    Key Record Dates
Last Update Posted: January 26, 2022
Last Verified: July 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immune Checkpoint Inhibitors
Molecular Mechanisms of Pharmacological Action